Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideALNYAlnylam Pharmaceuticals
FinDog View：Neutral
GILDGilead Sciences
FinDog View：Neutral
| Metric | ALNY | GILD |
|---|
| Close | 227.02 | 150.43 |
| Market Cap | $31.1B | $187B |
| 1M | −8.71% | +4.67% |
| P/E (TTM) | 38.5 | — |
| Forward P/E | 28.0 | 22.0 |
| P/E 5-Yr Percentile | — | — |
| P/S | 6.5 | 6.2 |
| P/B | 23.0 | 15.9 |
| Dividend Yield | — | 3.98% |
| Latest Quarter Revenue | $1.3B | $7.8B |
| Revenue YoY | +66.9% | +10.2% |
| Gross Margin | 76.9% | 79.8% |
| Latest Quarter EPS | 1.21 | -8.45 |
| Avg Post-Earnings Move | ±1.7% | ±3.8% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | — | 2.94% |
| 90-Day Net Insider Buying | −$0.40M | −$15.7M |
ALNY · Revenue, Last 8 Quarters ($B)
GILD · Revenue, Last 8 Quarters ($B)
